Amyris closes on potential $300M cannabinoid deal with biotech group Lavvan

Don’t believe the hype. Get realistic market forecasts, state by state insights and benchmarks for all cannabis sectors. Preorder the 2023 Factbook here. 

Amyris, a California-based company focused on wellness products, said it has closed a deal potentially worth $300 million with biotech startup Lavvan to research and develop synthetic cannabinoids.

The move follows that of Canada’s Cronos Group inking a $122 million deal with Boston-based Ginkgo Bioworks last September to produce lab-grown cannabinoids.

Analysts at Toronto-based Paradigm Capital said in a note that it expects a rash of deals in this sector to follow.

“Synthetic biology is becoming a cornerstone technology in the portfolios of forward-thinking companies,” Paradigm Capital wrote.

“Companies developing products solely from the cultivation of cannabis plants will find themselves unable to compete with the manifold advantages associated with industrial-scale cannabinoid biosynthesis.”

Amyris trades on the Nasdaq under the ticker symbol AMRS.

Lavvan is a privately held startup with executives from the pharmaceutical, financial and cannabis industries.

More details on the Amyris deal can be found here.